A J Bridges
Overview
Explore the profile of A J Bridges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bridges A
Biochem Soc Trans
. 2005 Mar;
33(Pt 2):343-5.
PMID: 15787602
The development of kinase and phosphatase inhibitors as novel therapeutic agents has been stimulated by the discovery that most biological processes are controlled by the reversible phosphorylation of proteins. Most...
2.
3.
Smaill J, Showalter H, Zhou H, Bridges A, McNamara D, FRY D, et al.
J Med Chem
. 2001 Jul;
44(3):429-40.
PMID: 11462982
4-Anilinoquinazoline- and 4-anilinopyrido[3,4-d]pyrimidine-6-acrylamides are potent pan-erbB tyrosine kinase inactivators, and one example (CI-1033) is in clinical trial. A series of analogues with a variety of Michael acceptor units at the...
4.
Ritland S, Gendler S, Burgart L, FRY D, Nelson J, Bridges A, et al.
Cancer Res
. 2000 Sep;
60(17):4678-81.
PMID: 10987266
A highly selective, p.o. bioavailable irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, N-[4-(3-chloro4-fluorophenylamino)-quinazolin-6-yl]-ac rylamide (CFPQA), was evaluated for its ability to prevent intestinal adenoma formation in ApcMin...
5.
Dietrich L, Bridges A, Albertini M
Med Oncol
. 2000 Mar;
17(1):64-9.
PMID: 10713663
An association between auto-immune disorders and interferon (IFN) has been reported. High levels of natural IFNalpha are present in the blood of patients with auto-immune disease and correlate with disease...
6.
Vincent P, Bridges A, Dykes D, FRY D, Leopold W, Patmore S, et al.
Cancer Chemother Pharmacol
. 2000 Feb;
45(3):231-8.
PMID: 10663641
Purpose: The involvement of the EGF receptor (EGFr) family of receptors in cancers suggests that a selective inhibitor of the tyrosine kinase activity of the EGFr family could have a...
7.
Showalter H, Bridges A, Zhou H, Sercel A, McMichael A, FRY D
J Med Chem
. 2000 Jan;
42(26):5464-74.
PMID: 10639288
Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series...
8.
Bridges A
Curr Med Chem
. 1999 Sep;
6(9):825-43.
PMID: 10495354
The Epidermal Growth Factor receptor (EGFr) was one of the first oncogenes identified, and it, or its ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor a (TGFa) are overexpressed...
9.
Smaill J, Palmer B, Rewcastle G, Denny W, McNamara D, Dobrusin E, et al.
J Med Chem
. 1999 May;
42(10):1803-15.
PMID: 10346932
A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors were prepared from the corresponding amino compounds by reaction with...
10.
Wilson R, Gluck O, Tesser J, Rice J, Meyer A, Bridges A
J Rheumatol
. 1999 Feb;
26(2):402-7.
PMID: 9972976
Objective: To determine the prevalence of antipolymer antibodies (APA) in patients with fibromyalgia (FM) and autoimmune disease control groups and to determine if the presence of these antibodies correlates with...